Standard Lithium Receives Notice of Allowance for Final U.S. Patent Covering DLE Process for Recovering Lithium From Brines
29. Dezember 2022 06:00 ET
|
Standard Lithium
VANCOUVER, British Columbia, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), a leading near-commercial...
Standard Lithium Receives Notice of Allowance for Final U.S. Patent Covering DLE Process for Recovering Lithium From Brines
29. Dezember 2022 03:01 ET
|
Standard Lithium
VANCOUVER, British Columbia, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), a leading near-commercial...
Standard Lithium Announces Notice of Allowance for U.S. Patents Covering DLE Process for Recovering Lithium From Brines
01. November 2022 06:00 ET
|
Standard Lithium
VANCOUVER, British Columbia, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), an innovative pre-commercial...
Standard Lithium Announces Notice of Allowance for U.S. Patents Covering DLE Process for Recovering Lithium From Brines
01. November 2022 03:01 ET
|
Standard Lithium
VANCOUVER, British Columbia, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), an innovative pre-commercial...
Kymab announces that the US Patent Trial and Appeal Board rejects a fifth request by Regeneron for invalidation of Kymab’s US patents
03. Juni 2020 07:00 ET
|
Kymab Group Ltd
Kymab announces that the US Patent Trial and Appeal Board rejects a fifthrequest by Regeneron for invalidation of Kymab’s US patents USPTO upholds a fifth Kymab patent covering Human Antibodies and...
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
31. Mai 2017 07:30 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 31, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) announced today the issuance of European Patent No. 1615623 titled...
Elite Pharmaceuticals Awarded Second Canadian Patent for Abuse Deterrent Drug Formulation
16. Dezember 2014 08:38 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Dec. 16, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the continued expansion of Elite's intellectual property...